$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000155837023013483 Filed on August 07, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$10.35M	$35.08M	$8.753M
YoY Change	-27.06%	300.72%	36.19%
Cost Of Revenue	$4.893M	$6.148M	$4.087M
YoY Change	-30.83%	50.43%	-13.65%
Gross Profit	$5.452M	$28.93M	$4.666M
YoY Change	-23.31%	519.95%	175.44%
Gross Profit Margin	52.7%	82.47%	53.31%
Selling, General & Admin	$3.670M	$4.031M	$2.611M
YoY Change	28.86%	54.39%	-17.66%
% of Gross Profit	67.31%	13.94%	55.96%
Research & Development	$3.669M	$4.475M	$7.579M
YoY Change	-50.32%	-40.96%	-1.43%
% of Gross Profit	67.3%	15.47%	162.43%
Depreciation & Amortization	$308.0K	$290.0K	$270.0K
YoY Change	14.07%	7.41%	-3.57%
% of Gross Profit	5.65%	1.0%	5.79%
Operating Expenses	$7.339M	$8.506M	$10.19M
YoY Change	-28.29%	-16.53%	-6.17%
Operating Profit	-$1.887M	$20.42M	-$5.524M
YoY Change	-39.62%	-469.68%	-39.73%
Interest Expense	$168.0K	-$770.0K	$190.0K
YoY Change	-138.18%	-505.26%	-109.13%
% of Operating Profit		-3.77%
Other Income/Expense, Net	$168.0K	-$774.0K	$190.0K
YoY Change	-138.01%	-507.37%	-109.16%
Pretax Income	-$1.719M	$19.65M	-$5.334M
YoY Change	-51.85%	-468.34%	-52.54%
Income Tax	$133.0K	$308.0K
% Of Pretax Income		1.57%
Net Earnings	-$1.852M	$19.34M	-$5.334M
YoY Change	-48.08%	-462.56%	-52.55%
Net Earnings / Revenue	-17.9%	55.14%	-60.94%
Basic Earnings Per Share	-$0.03	$0.29	-$0.11
Diluted Earnings Per Share	-$0.04	$0.21	-$0.11
COMMON SHARES
Basic Shares Outstanding	71.58M	65.41M	47.33M
Diluted Shares Outstanding	83.78M	83.20M	47.33M

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.41M	$48.20M	$12.50M
YoY Change	90.73%	285.6%	-63.13%
Cash & Equivalents	$20.41M	$48.18M	$12.49M
Short-Term Investments
Other Short-Term Assets	$1.125M	$1.708M	$2.597M
YoY Change	-35.2%	-34.23%	-13.81%
Inventory	$21.58M	$19.64M	$16.51M
Prepaid Expenses
Receivables	$8.935M	$4.049M	$2.022M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$72.62M	$73.58M	$49.70M
YoY Change	58.69%	48.04%	-48.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.684M	$4.637M	$4.768M
YoY Change	0.15%	-2.75%	-4.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.352M	$4.400M	$1.400M
YoY Change	210.86%	214.29%	-26.32%
Total Long-Term Assets	$14.95M	$14.84M	$10.94M
YoY Change	36.55%	35.66%	-10.92%
TOTAL ASSETS
Total Short-Term Assets	$72.62M	$73.58M	$49.70M
Total Long-Term Assets	$14.95M	$14.84M	$10.94M
Total Assets	$87.57M	$88.42M	$60.64M
YoY Change	54.42%	45.81%	-43.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.74M	$18.55M	$7.000M
YoY Change	234.64%	164.93%	14.75%
Accrued Expenses	$9.249M	$8.608M	$1.100M
YoY Change	824.9%	682.55%	-8.33%
Deferred Revenue			$10.22M
YoY Change			-43.55%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.19M
YoY Change
Total Short-Term Liabilities	$43.36M	$23.11M	$30.96M
YoY Change	26.4%	-25.36%	-67.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$20.10M	$28.00M
YoY Change	-100.0%	-28.21%
Other Long-Term Liabilities	$5.963M	$6.200M	$11.50M
YoY Change	2.81%	-46.09%	30163.16%
Total Long-Term Liabilities	$5.963M	$26.31M	$39.57M
YoY Change	-82.42%	-33.52%	387.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.36M	$23.11M	$30.96M
Total Long-Term Liabilities	$5.963M	$26.31M	$39.57M
Total Liabilities	$49.32M	$49.42M	$70.53M
YoY Change	-27.7%	-29.94%	-32.42%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.25M	$39.00M	-$9.889M
YoY Change
Total Liabilities & Shareholders Equity	$87.57M	$88.42M	$60.64M
YoY Change	54.42%	45.81%	-43.96%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$1.852M	$19.34M	-$5.334M
YoY Change	-48.08%	-462.56%	-52.55%
Depreciation, Depletion And Amortization	$308.0K	$290.0K	$270.0K
YoY Change	14.07%	7.41%	-3.57%
Cash From Operating Activities	-$6.893M	$4.980M	-$7.360M
YoY Change	-25.08%	-167.66%	-213.06%
INVESTING ACTIVITIES
Capital Expenditures	$449.0K	$200.0K	$130.0K
YoY Change	648.33%	53.85%	-53.57%
Acquisitions
YoY Change
Other Investing Activities	-$20.43M	-$20.00K	$490.0K
YoY Change	-442.21%	-104.08%	-93.73%
Cash From Investing Activities	-$20.88M	-$220.0K	$360.0K
YoY Change	-453.28%	-161.11%	-95.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.000K	10.44M	2.640M
YoY Change	-100.26%	295.45%
NET CHANGE
Cash From Operating Activities	-6.893M	4.980M	-7.360M
Cash From Investing Activities	-20.88M	-220.0K	360.0K
Cash From Financing Activities	-4.000K	10.44M	2.640M
Net Change In Cash	-27.78M	15.20M	-4.360M
YoY Change	1469.27%	-448.62%	-131.03%
FREE CASH FLOW
Cash From Operating Activities	-$6.893M	$4.980M	-$7.360M
Capital Expenditures	$449.0K	$200.0K	$130.0K
Free Cash Flow	-$7.342M	$4.780M	-$7.490M
YoY Change	-20.71%	-163.82%	-220.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33357
	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0643773
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 University Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
	dei	Entity Address City Or Town EntityAddressCityOrTown	Hackensack
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07601
	dei	City Area Code CityAreaCode	201
	dei	Local Phone Number LocalPhoneNumber	696-9345
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	PLX
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71580762
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48184000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17111000
CY2022Q4	plx	Short Term Bank Deposits ShortTermBankDeposits	5069000
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4049000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4586000
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1708000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1310000
CY2023Q2	us-gaap	Inventory Net InventoryNet	19635000
CY2022Q4	us-gaap	Inventory Net InventoryNet	16804000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	20421000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5524000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	73576000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	44880000
CY2023Q2	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1268000
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1267000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4637000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4553000
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3130000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5806000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5087000
CY2023Q2	us-gaap	Assets Assets	88417000
CY2022Q4	us-gaap	Assets Assets	55787000
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3304000
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5862000
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	18545000
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	12271000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1260000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1118000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13178000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	23109000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32429000
CY2023Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	20132000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	28187000
CY2023Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1598000
CY2022Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1642000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4577000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4169000
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	26307000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	33998000
CY2023Q2	us-gaap	Liabilities Liabilities	49416000
CY2022Q4	us-gaap	Liabilities Liabilities	66427000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	39001000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10640000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88417000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55787000
	us-gaap	Revenues Revenues	44663000
	us-gaap	Revenues Revenues	24838000
CY2023Q2	us-gaap	Revenues Revenues	35075000
CY2022Q2	us-gaap	Revenues Revenues	8753000
	us-gaap	Cost Of Revenue CostOfRevenue	9233000
	us-gaap	Cost Of Revenue CostOfRevenue	10121000
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	6148000
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	4087000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10322000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16346000
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4475000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7579000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7146000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5765000
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4031000
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2611000
	us-gaap	Operating Income Loss OperatingIncomeLoss	17962000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7394000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2169000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1242000
CY2023Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1305000
CY2022Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	623000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	918000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1016000
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	531000
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	813000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1251000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-226000
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-774000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	190000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16711000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7620000
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	19647000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5334000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	503000
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	308000
	us-gaap	Net Income Loss NetIncomeLoss	16208000
	us-gaap	Net Income Loss NetIncomeLoss	-7620000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	19339000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5334000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62378745
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46589976
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67158628
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47327952
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78896220
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46589976
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83200641
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47327952
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6036000
	plx	Stock Issued During Period Value Sales Agreement StockIssuedDuringPeriodValueSalesAgreement	2641000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	293000
	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	831000
	plx	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	2000
	us-gaap	Net Income Loss NetIncomeLoss	-7620000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9889000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10640000
	plx	Stock Issued During Period Value Sales Agreement StockIssuedDuringPeriodValueSalesAgreement	23954000
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7783000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	812000
	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	172000
	plx	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	712000
	us-gaap	Net Income Loss NetIncomeLoss	16208000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	39001000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-7486000
CY2022Q2	plx	Stock Issued During Period Value Sales Agreement StockIssuedDuringPeriodValueSalesAgreement	2641000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	144000
CY2022Q2	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	144000
CY2022Q2	plx	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	2000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5334000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9889000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1008000
CY2023Q2	plx	Stock Issued During Period Value Sales Agreement StockIssuedDuringPeriodValueSalesAgreement	9721000
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7783000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	359000
CY2023Q2	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	79000
CY2023Q2	plx	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	712000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	19339000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	39001000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	144000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	144000000
	us-gaap	Profit Loss ProfitLoss	16208000
	us-gaap	Profit Loss ProfitLoss	-7620000
	us-gaap	Share Based Compensation ShareBasedCompensation	984000
	us-gaap	Share Based Compensation ShareBasedCompensation	1124000
	us-gaap	Depreciation Depreciation	573000
	us-gaap	Depreciation Depreciation	538000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	152000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	952000
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	36000
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	-449000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3130000
	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	27000
	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	-16000
	plx	Gain Loss On Debt Conversion GainLossOnDebtConversion	421000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	148000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	146000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13178000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2644000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-119000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-76000
	plx	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	-3000
	plx	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	3000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2831000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1447000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3643000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4864000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1975000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13185000
	plx	Increase Decrease In Bank Deposits IncreaseDecreaseInBankDeposits	16000000
	plx	Proceeds From Sale Of Short Term Deposits ProceedsFromSaleOfShortTermDeposits	5000000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	452000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	357000
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	38000
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-457000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4510000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15900000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23954000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2641000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	712000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24666000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2643000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-78000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-51000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31073000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26493000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17111000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38985000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48184000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12492000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	348000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	81000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1079000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	99000
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7783000
	us-gaap	Interest Paid Net InterestPaidNet	1977000
	us-gaap	Interest Paid Net InterestPaidNet	1120000
	plx	Interest Received Net InterestReceivedNet	78000
	plx	Interest Received Net InterestReceivedNet	93000
CY2023Q2	plx	Number Of Global Licensing And Supply Agreements NumberOfGlobalLicensingAndSupplyAgreements	2
CY2023Q2	plx	Number Of Patients Enrolled NumberOfPatientsEnrolled	126
CY2023Q2	plx	Number Of Patients Actively Participating NumberOfPatientsActivelyParticipating	116
CY2023Q1	plx	Number Of Patients Dosed NumberOfPatientsDosed	13
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4352000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3508000
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3318000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2678000
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11965000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10618000
CY2023Q2	us-gaap	Inventory Net InventoryNet	19635000
CY2022Q4	us-gaap	Inventory Net InventoryNet	16804000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	144000000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	185000000
CY2023Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	700000
CY2023Q2	plx	Stock Issued During Period Shares Warrants Exercises StockIssuedDuringPeriodSharesWarrantsExercises	237012
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	845000
CY2023Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	19339000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5334000
	us-gaap	Net Income Loss NetIncomeLoss	16208000
	us-gaap	Net Income Loss NetIncomeLoss	-7620000
CY2023Q2	us-gaap	Dilutive Securities DilutiveSecurities	-1749000
	us-gaap	Dilutive Securities DilutiveSecurities	-2053000
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	17590000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5334000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	14155000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7620000
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67158628
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47327952
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62378745
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46589976
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	14355621
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	15274121
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1555307
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1243354
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	131085
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83200641
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47327952
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78896220
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46589976
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	781000
CY2023Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	3163000
CY2023Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3438000
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3633000
CY2023Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3130000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3130000
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	308000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	503000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.03
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q2	plx	Milestone Payment To Regulatory Approvals MilestonePaymentToRegulatoryApprovals	20000000.0
CY2023Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3100000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1223000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1216000
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	506000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	719000
CY2023Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1526000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1404000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8608000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7478000
CY2023Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1262000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	530000
CY2023Q2	plx	Reserve For Deductions From Revenue Current ReserveForDeductionsFromRevenueCurrent	1909000
CY2023Q2	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	348000
CY2022Q4	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	143000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	18545000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12271000

Files In Submission

Name	View Source	Status
0001558370-23-013483-index-headers.html	Edgar Link	pending
0001558370-23-013483-index.html	Edgar Link	pending
0001558370-23-013483.txt	Edgar Link	pending
0001558370-23-013483-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plx-20230630.xsd	Edgar Link	pending
plx-20230630x10q.htm	Edgar Link	pending
plx-20230630x10q005.jpg	Edgar Link	pending
plx-20230630x10q006.jpg	Edgar Link	pending
plx-20230630x10q007.jpg	Edgar Link	pending
plx-20230630xex10d1.htm	Edgar Link	pending
plx-20230630xex31d1.htm	Edgar Link	pending
plx-20230630xex31d2.htm	Edgar Link	pending
plx-20230630xex32d1.htm	Edgar Link	pending
plx-20230630xex32d2.htm	Edgar Link	pending
plx-20230630xex3d6.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
plx-20230630_def.xml	Edgar Link	unprocessable
plx-20230630_pre.xml	Edgar Link	unprocessable
plx-20230630x10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
plx-20230630_cal.xml	Edgar Link	unprocessable
plx-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2023 Q3 Form 10-Q Financial Statement

#000155837023013483 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2023 Q3 Form 10-Q Financial Statement

#000155837023013483 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx